
What does -prazole mean?
The -prazole stem marks a proton pump inhibitor. Why irreversible binding makes the effect outlast the drug, why dosing is before food, and the CYP2C19 trap.

Short answer: A drug ending in -azepam or -azolam is a benzodiazepine: it binds an allosteric site on the GABA-A receptor and increases how often the chloride channel opens in response to GABA. Because it cannot open the channel without GABA, its effect has a ceiling, and that ceiling is why benzodiazepine overdose alone is usually survivable when barbiturate overdose is not.
Generic drug names are not invented freely. The USAN Council assigns stems so that related compounds share a family name, stating plainly that the purpose is to make prescribing safer by giving immediate recognition. The WHO INN Stem Book does the same job internationally. The two endings reflect ring chemistry rather than a difference in action. The -azepam drugs are 1,4-benzodiazepines and the -azolam drugs carry a fused triazolo ring, which tends to shorten their duration. Both behave the same way at the receptor, so for pharmacology purposes they are one family.
GABA-A is a ligand-gated chloride channel and the main inhibitory receptor in the central nervous system. When GABA binds, the channel opens, chloride flows in, the neuron becomes more negative inside and is therefore harder to fire. Almost every sedative in clinical use works by amplifying this one mechanism somewhere, which is why sedatives from unrelated chemical families produce such similar effects and such dangerous combinations.
Benzodiazepines increase how often the channel opens. Barbiturates increase how long it stays open, and at high concentrations they can open it without GABA present at all. That last property removes the ceiling. A benzodiazepine can only amplify a signal GABA has already started, so once every receptor is potentiated, more drug adds little. This single distinction explains why one class replaced the other in clinical practice.
The protection is real and it is also conditional. Opioids depress respiration through a different mechanism in the brainstem, and alcohol acts at GABA-A among other targets, so combining any of them stacks inhibition by separate routes. The ceiling on one drug does not cap the total. This is the mechanism behind a large share of sedative-related deaths, and it is why the combination carries specific warnings rather than general caution.
All members share the mechanism, so the choice between them is pharmacokinetic. Diazepam is oxidised into active metabolites that are themselves long lived, so repeated doses accumulate. Lorazepam, oxazepam and temazepam are conjugated directly and produce no active metabolites. Oxidative capacity falls early in liver disease while conjugation is relatively preserved, which is why that second group is preferred when hepatic function is impaired.
Ageing reduces oxidative metabolism and increases sensitivity to central depressants at the same time, so a long-acting agent with active metabolites accumulates in exactly the people least able to tolerate it. The result is falls, fractures and confusion rather than simple drowsiness. This is why long-acting benzodiazepines appear on most published lists of medicines to avoid in older adults, and why any prescription in that group is meant to be short.
Most drugs of dependence produce an unpleasant withdrawal. Benzodiazepine withdrawal after prolonged use can produce seizures and is potentially life threatening, which places it in a small category alongside alcohol. Sudden cessation is therefore not a neutral act, and tapering, often by switching to a longer-acting agent whose slow offset smooths the decline, is the standard approach rather than a courtesy.
Since every member works the same way at the receptor, the table below separates them on the properties that actually drive prescribing.
| Drug | Metabolism | Typical use |
|---|---|---|
| Diazepam | Oxidation, long-lived active metabolites | Alcohol withdrawal, muscle spasm |
| Lorazepam | Conjugation only, no active metabolites | Status epilepticus, liver impairment |
| Temazepam | Conjugation only | Short-term insomnia |
| Midazolam | Rapid, short acting | Procedural sedation |
| Chlordiazepoxide | Long acting | Alcohol withdrawal regimens |
Flumazenil occupies the benzodiazepine site without activating it, displacing the drug by competition. That sounds like an obvious antidote and it is used cautiously, because abruptly removing benzodiazepine activity can precipitate seizures in someone dependent on them, and in mixed overdose it can unmask the proconvulsant effects of whatever else was taken. Supportive care is often the safer answer.
Meeting an unfamiliar -azepam tells you the mechanism, that the overdose ceiling applies unless something else is on board, that tolerance and dependence are expected pharmacology rather than moral failure, and that the specific drug choice is probably a question about liver function or duration. The stem does not tell you the half-life, which is the one thing you have to learn per drug.
Tolerance does not arrive at the same rate for every effect. Sedation and the anticonvulsant action wane comparatively quickly, within days to weeks of regular use, while the anxiolytic effect is better retained. That mismatch is clinically awkward, because the effect a patient is taking the drug for may persist while the effect that made it feel obviously powerful fades. It also means a dose that once controlled seizures may no longer do so, which matters when these drugs are used as maintenance anticonvulsants.
Benzodiazepines shorten the time taken to fall asleep and reduce night-time waking, which looks like success. They also suppress slow-wave sleep and alter REM, so the architecture of the night changes even though its duration improves. Patients often report sleeping longer while feeling no more rested, and stopping the drug produces a rebound in the suppressed stages that feels like severe insomnia. This is why guidance limits use to short courses rather than because of dependence alone.
Zopiclone, zolpidem and zaleplon are chemically unrelated to the benzodiazepines and carry no shared stem, yet they bind the same receptor complex at the same site, with more selectivity for particular subunit combinations. They were introduced on the expectation that this selectivity would avoid dependence and tolerance, and in practice the difference has proved smaller than hoped. A stem tells you about chemistry, so a drug can share a mechanism without sharing an ending.
Equivalent doses across this class differ by an order of magnitude. Roughly half a milligram of lorazepam is in the region of five milligrams of diazepam, so a number that looks small is not necessarily a small dose. Switching between agents without consulting an equivalence table is a recognised source of both oversedation and withdrawal, and it is a place where the reassuring familiarity of the shared stem actively misleads.
The class page sets out the mechanism in full, and the pairing of a long-acting agent against a conjugated one is where most exam questions land, so read diazepam versus lorazepam next. Anticholinergic burden is a related problem in the same population. The practice set will show you whether the distinction holds under time.
The method below works for any generic name, which is the point of learning naming as a system rather than learning drugs one at a time. Start at the end of the word, because that is where the stem almost always sits, and read backwards until you reach something familiar. Endings are assigned; beginnings are usually the manufacturer distinguishing one compound from its siblings, so the front of the name carries far less information.
Next, ask what the stem predicts. A good stem gives you a target or a chemical family, and from either you can usually derive the main effect and the principal side effect, because most adverse effects are the intended action appearing in a tissue where it was not wanted. Then look deliberately for the exception, since every stem has one and exams are built on exactly those cases.
Finally, check rather than assume. A stem narrows the possibilities; it does not replace the label. Drugs that share a target can carry different stems if their chemistry differs, and drugs that share a stem can differ enormously in duration, which is frequently the property that decides how each is used. Treat the ending as a strong hypothesis that gets you most of the way to an answer, then confirm the detail against a primary source before it matters clinically.
It marks a benzodiazepine, a positive allosteric modulator at the GABA-A receptor that increases how often the chloride channel opens. The related -azolam ending marks the same family with a fused triazolo ring, which tends to shorten duration.
Benzodiazepines increase how often the channel opens but still require GABA to be present, which puts a ceiling on their effect. Barbiturates increase how long it stays open and at high doses can open it without GABA, removing that ceiling.
Lorazepam, oxazepam and temazepam are cleared by conjugation alone, which is relatively preserved in hepatic impairment, and they produce no active metabolites. Diazepam requires oxidative metabolism and accumulates.
It can be. Unlike most drugs of dependence, abrupt withdrawal after prolonged use can cause seizures, so treatment is tapered and often switched to a longer-acting agent first.
Removing benzodiazepine activity abruptly can precipitate seizures in a dependent patient, and in mixed overdose it can unmask the effects of other ingested drugs. It is reserved for selected cases.
The stem gives you a receptor, a mechanism and a safety profile, and it also gives you the reason an entire older class was abandoned. What it does not give you is the half-life, and since the clinical choice between benzodiazepines is almost entirely a question of duration and metabolic route, that is the part worth learning drug by drug. Everything else you can derive.
For study only. This article is written for learning and examination practice. It is not medical advice, not clinical decision support, and must never be used to make a decision about a real patient. Always verify against your local formulary, the product literature and a qualified pharmacist.
One mechanism explained properly every day, then brought back before you forget it.
Free to download. 7-day Pro trial. No credit card.